Neurocrine Biosciences
NBIX
NBIX
591 hedge funds and large institutions have $12.9B invested in Neurocrine Biosciences in 2024 Q2 according to their latest regulatory filings, with 80 funds opening new positions, 251 increasing their positions, 188 reducing their positions, and 67 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0% more capital invested
Capital invested by funds: $12.9B → $12.9B (+$22.7M)
0.75% less ownership
Funds ownership: 93.79% → 93.04% (-0.75%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Holders
591
Holding in Top 10
8
Calls
$125M
Puts
$53.6M
Top Buyers
| 1 | +$85.1M | |
| 2 | +$69.4M | |
| 3 | +$69.4M | |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$63.6M |
| 5 |
BlackRock
New York
|
+$59.2M |
Top Sellers
| 1 | -$115M | |
| 2 | -$97.9M | |
| 3 | -$71.7M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$56.1M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$49.1M |